{
  "query": "What is the role of CTLA-4 inhibitors?",
  "response": "CTLA-4 inhibitors (ipilimumab) work earlier in immune activation than PD-1 inhibitors. Combination ipilimumab + nivolumab shows higher response rates (58% in melanoma) but increased toxicity (59% grade 3-4 adverse events). Reserved for specific indications.",
  "attention": {
    "sources": [
      "CTLA4-mechanism.pdf",
      "ipilimumab-trials.pdf"
    ],
    "weights": [
      0.6,
      0.4
    ],
    "patterns": [
      "sources:2",
      "outcome:success"
    ]
  },
  "outcome": "success",
  "confidence": 0.86,
  "timestamp": 1760058208797,
  "memory_type": "long-term",
  "id": "62878fd8ea976ec38a6465163b125b6d13287bf1d7d7e56c16e4f19e32215f9b"
}